July 2007
Volume 2, Issue 7
Virtual Screening
     
Drug Discovery Today Banner

Drug Discovery Today    Latest issue    DDT home    
echoice

FEATURED
CONFERENCES


NeuroDrug 2007

NeuroDrug


R&D Leaders Forum


R&D Leaders Forum

Oncology Leaders' Forum 2007

BioTrinity 2007

Royal Society of Tropical Medicine and Hygiene 2007
a
BioTrinity 2007



RELATED
JOBS


Computational Chemist
Pfizer Inc.
St Louis, MO, US

Associate Computational Biologist
Massachusetts Institute of Technology
Cambridge, MA, US

Senior Computer Biologists
The Wellcome Trust Sanger Institute
Hinxton, UK

David Clark
The View from Here
David Clark

Virtual screening (VS) is the computational counterpart of biochemical high-throughput screening (HTS). Using specialised computer programs, large numbers of chemical compounds are assessed...
Read more...

Upcoming Issues


Issue 8
August '07
Druggability

Issue 9
September '07
Chemoinformatics

Issue 10
October '07
Orphan Diseases

Editor's Choice

Sign Up for email

Update your details

Unsubscribe

Contact Us




xPharm

Your first stop for reliable, authoritative information on all aspects of pharmacology. Sign up today for a free, 14-day evaluation.



A review of 2006


  Top Reviews
Advances in virtual screening

Muegge I and Oloff S
Drug Discovery Today: Technologies

Although the term virtual screening as the in silico analog of high throughput screening has been coined only a decade ago, virtual screening is now a widespread lead identification method in the pharmaceutical industry. A myriad of different methods have been developed exploiting the growing library of target structures and assay data as a basis for finding new lead structures...

Molecular similarity analysis in virtual screening: Foundations, limitations and novel approaches

Eckert H and Bajorath J
Drug Discovery Today

The success of ligand-based virtual-screening calculations is influenced highly by the nature of target-specific structure–activity relationships. This might pose severe constraints on the ability to recognize diverse structures with similar activity...

Virtual ligand screening: strategies, perspectives and limitations

Klebe G
Drug Discovery Today

In contrast to high-throughput screening, in virtual ligand screening (VS), compounds are selected using computer programs to predict their binding to a target receptor. A key prerequisite is knowledge about the spatial and energetic criteria responsible for protein–ligand binding. The concepts and prerequisites to perform VS are summarized here...


  Abstracts of Key Research Articles

Ligand docking and structure-based virtual screening in drug discovery
Cavasotto CN, Orry AJW
Curr Top Med Chem. 2007;7(10):1006-1014.

Virtual high-throughput screening of molecular databases
Seifert MHJ, Kraus J, Kramer B
Curr Opin Drug Discov Devel. 2007;10(3):298-307

Comparison of shape-matching and docking as virtual screening tools
Hawkins PCD, Skillman AG, Nicholls A
J Med Chem. 2007; 50(1):74-82

Benchmarking sets for molecular docking
Huang N, Shoichet BK, Irwin JJ
J Med Chem. 2006; 49(23):6789-6801

Scoring functions for protein-ligand docking
Jain, AN
Curr Protein Pept Sci. 2006;7(5):407-420

Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes
Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT
J Med Chem. 2006;49(21):6177-6196

Minimizing false positives in kinase virtual screens
Perola E
Proteins. 2006; 64(2):422-435

On evaluating molecular-docking methods for pose prediction and enrichment factors
Chen H, Lyne PD, Giordanetto F, Lovell T, Li J
J Chem Inf Model. 2006; 46(1):401-415

Screening drug-like compounds by docking to homology models: a systematic study
Kairys V, Fernandes MX, Gilson MK
J Chem Inf Model. 2006; 46(1):365-379

A critical assessment of docking programs and scoring functions
Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, Lambert MH, Lindvall M, Nevins N, Semus SF, Senger S, Tedesco G, Wall ID, Woolven JM, Peishoff CE, Head MS
J Med Chem. 2006; 49(20):5912-5931


Data Protection Notice:

This email has been sent to email-address from Elsevier Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, registered in England with registered number 1982084, using Email Reaction’s Technology and Platform.

You are receiving this email because you were a registered user of BioMedNet and requested to receive Gateway Alerts or are a subscriber to Drug Discovery Today. To unsubscribe from this email alert service or sign up for others, click here.

For all inquiries, problems or suggestions regarding this service, please contact DDT@drugdiscoverytoday.com

Copyright © 2007 Elsevier Ltd. All rights reserved. Please read the Elsevier Alerts Privacy Policy and the E-Mail Reaction Privacy Policy.